Mechanisms of liver involvement in systemic disease

Best Practice and Research: Clinical Gastroenterology

Volumn 27, Issue 4, 2013, Pages 471-483

  Edwards, Lori ^a,c,d   Wanless, Ian R ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^d CREDIT VALLEY HOSPITAL   (Canada)

Author keywords

Apoptosis; Cytokines; Hyperinsulinism; Hypertension, portal; Immunity, adaptive; Immunity, innate; Liver cirrhosis; Liver ischaemia; Obesity; Reactive oxygen species

Indexed keywords

CYTOKINE; ENDOTOXIN; INSULIN; OXALIPLATIN;

ADAPTIVE IMMUNITY; ARTICLE; BLOOD VESSEL INJURY; BLOOD VESSEL OCCLUSION; CHOLESTASIS; CONGESTIVE HEART FAILURE; GENETIC PREDISPOSITION; HELLP SYNDROME; HEMOPHAGOCYTIC SYNDROME; HEPATITIS; HUMAN; HYPERINSULINEMIA; INNATE IMMUNITY; LIVER CELL; LIVER DISEASE; LIVER INJURY; LIVER NECROSIS; LIVER TRANSPLANTATION; NECROSIS; NUTRITION; OVERNUTRITION; REPERFUSION INJURY; SEPSIS; SHOCK; SINUSOIDAL ENDOTHELIAL NECROSIS; SYSTEMIC DISEASE;

EID: 84885189573     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2013.08.002     Document Type: Review

References (81)

1. Gelbmann CM, Rummele P, Wimmer M, Hofstadter F, Gohlmann B, Endlicher E, et al. Ischemic-like cholangiopathy with secondary sclerosing cholangitis in critically ill patients. Am J Gastroenterol 2007;102:1221-9 (Pubitemid 46802001)
2. Baskin-Bey ES, Washburn K, Feng S, Oltersdorf T, Shapiro D, Huyghe M, et al. Clinical trial of the pan-caspase inhibitor, IDN-6556, in human liver preservation injury. Am J Transplant 2007;7:218-25 (Pubitemid 44952876)
3. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009;50:1072-8
4. Lemasters JJ. Mechanisms of hepatic toxicitiy V. Necrapoptosis and the mitochondrial permeability transition: shared pathways to necrosis and apoptosis. Am J Physiol 1999;276:G1-6 (Pubitemid 29063592)
5. Kim JS,Wang JH, Lemasters JJ. Mitochondrial permeability transition in rat hepatocytes after anoxia/reoxygenation: role of Ca2?-dependent mitochondrial formation of reactive oxygen species. Am J Physiol Gastrointest Liver Physiol 2012;302: G723-31
6. de Rougemont O, Dutkowski P, Clavien PA. Biological modulation of liver ischemia-reperfusion injury. Curr Opin Organ Transplant 2010;15:183-9
7. Perry BC, Soltys D, Toledo AH, Toledo-Pereyra LH. Tumor necrosis factor-alpha in liver ischemia/reperfusion injury. J Invest Surg 2011;24:178-88
8. Jaeschke H, Woolbright BL. Current strategies to minimize hepatic ischemia-reperfusion injury by targeting reactive oxygen species. Transplant Rev 2012;26:103-14
9. Henrion J. Hypoxic hepatitis. Liver Int 2012;32:1039-52
10. Lesurtel M, Lehmann K, de Rougemont O, Clavien PA. Clamping techniques and protecting strategies in liver surgery. HPB - Off J Int Hepato Pancreato Biliary Assoc 2009;11:290-5
11. Bahde R, Spiegel HU. Hepatic ischaemia-reperfusion injury from bench to bedside. Br J Surg 2010;97:1461-75
12. de Rougemont O, Lehmann K, Clavien PA. Preconditioning, organ preservation, and postconditioning to prevent ischemiareperfusion injury to the liver. Liver Transpl 2009;15:1172-82
13. Aldrighetti L, Pulitano C, Arru M, Finazzi R, Catena M, Soldini L, et al. Impact of preoperative steroids administration on ischemia-reperfusion injury and systemic responses in liver surgery: a prospective randomized study. Liver Transpl 2006; 12:941-9 (Pubitemid 43960370)
14. Kotsch K, Ulrich F, Reutzel-Selke A, Pascher A, Faber W, Warnick P, et al. Methylprednisolone therapy in deceased donors reduces inflammation in the donor liver and improves outcome after liver transplantation: a prospective randomized controlled trial. Ann Surg 2008;248:1042-50
15. Defamie V, Laurens M, Patrono D, Devel L, Brault A, Saint-Paul MC, et al. Matrix metalloproteinase inhibition protects rat livers from prolonged cold ischemia-warm reperfusion injury. Hepatology 2008;47:177-85 (Pubitemid 351171055)
16. Selzner N, Rudiger H, Graf R, Clavien PA. Protective strategies against ischemic injury of the liver. Gastroenterology 2003; 125:917-36 (Pubitemid 37070708)
17. McKay A, Cassidy D, Sutherland F, Dixon E. Clinical results of N-acetylcysteine after major hepatic surgery: a review. J Hepatobiliary Pancreat Surg 2008;15:473-8
18. Lang Jr JD, Teng X, Chumley P, Crawford JH, Isbell TS, Chacko BK, et al. Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. J Clin Invest 2007;117:2583-91 (Pubitemid 47494359)
19. Beck-Schimmer B, Breitenstein S, Urech S, De Conno E, Wittlinger M, Puhan M, et al. A randomized controlled trial on pharmacological preconditioning in liver surgery using a volatile anesthetic. Ann Surg 2008;248:909-18
20. Wanless IR, Liu JJ, Butany J. Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis). Hepatology 1995;21:1232-7
21. Wanless IR, HuangW-Y. Vascular disorders. In: Burt AD, Portmann BC, Ferrell L, editors. MacSween?s pathology of the liver. 6th ed. Edinburgh: Churchill-Livingstone-Elsevier; 2012. p. 601-43
22. Kakar S, Batts KP, Poterucha JJ, Burgart LJ. Histologic changes mimicking biliary disease in liver biopsies with venous outflow impairment. Mod Pathol 2004;17:874-8 (Pubitemid 38843372)
23. Wanless IR, Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis 2004;24: 99-106 (Pubitemid 38496052)
24. Deleve LD,Wang X, Tsai J, Kanel G, Strasberg S, Tokes ZA. Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition. Gastroenterology 2003;125:882-90 (Pubitemid 37070704)
25. Ezzat T, van den Broek MA, Davies N, Dejong CH, Bast A, Malago M, et al. The flavonoid monoHER prevents monocrotalineinduced hepatic sinusoidal injury in rats. J Surg Oncol 2012;106:72-8
26. Robinson SM, Mann J, Vasilaki A, Mathers J, Burt AD, Oakley F, et al. Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model. J Hepatol 2013;59:318-26
27. Brouquet A, Benoist S, Julie C, Penna C, Beauchet A, Rougier P, et al. Risk factors for chemotherapy-associated liver injuries: a multivariate analysis of a group of 146 patients with colorectal metastases. Surgery 2009;145:362-71
28. Nakamura K, Hatano E, Narita M, Miyagawa-Hayashino A, Koyama Y, Nagata H, et al. Sorafenib attenuates monocrotalineinduced sinusoidal obstruction syndrome in rats through suppression of JNK and MMP-9. J Hepatol 2012;57:1037-43
29. Wanless IR, Takayama T. Focal nodular hyperplasia is a response to artery-to-portal vein shunt causing arterialization and congestive injury that explains the map-like pattern of glutamine synthetase. Hepatology 2013;58
30. Tucker ON, Heaton N. The ?small for size? liver syndrome. Curr Opin Crit Care 2005;11:150-5
31. Petrasek J, Csak T, Szabo G. Toll-like receptors in liver disease. Adv Clin Chem 2013;59:155-201
32. Szabo G, Romics Jr L, Frendl G. Liver in sepsis and systemic inflammatory response syndrome. Clin Liver Dis 2002;6:1045-66 (Pubitemid 36026462)
33. Kowalewska PM, Patrick AL, Fox-Robichaud AE. Innate immunity of the liver microcirculation. Cell Tissue Res 2011;343: 85-96
34. Nolan JP. The role of intestinal endotoxin in liver injury: a long and evolving history. Hepatology 2010;52:1829-35
35. Schaffert CS, Duryee MJ, Hunter CD, Hamilton 3rd BC, DeVeney AL, Huerter MM, et al. Alcohol metabolites and lipopolysaccharide: roles in the development and/or progression of alcoholic liver disease.World J Gastroenterol - WJG 2009; 15:1209-18
36. Mandrekar P, Szabo G. Signalling pathways in alcohol-induced liver inflammation. J Hepatol 2009;50:1258-66
37. Szabo G, Bala S. Alcoholic liver disease and the gut-liver axis. World J Gastroenterol - WJG 2010;16:1321-9
38. Miller AM, Horiguchi N, Jeong WI, Radaeva S, Gao B. Molecular mechanisms of alcoholic liver disease: innate immunity and cytokines. Alcohol Clin Exp Res 2011;35:787-93
39. Moseley RH. Sepsis and cholestasis. Clin Liver Dis 1999;3:465-75
40. Fuchs M, Sanyal AJ. Sepsis and cholestasis. Clin Liver Dis 2008;12:151-72 ix (Pubitemid 351163137)
41. Spirli C, Fabris L, Duner E, Fiorotto R, Ballardini G, Roskams T, et al. Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology 2003;124:737-53 (Pubitemid 36268491)
42. Spirli C, Nathanson MH, Fiorotto R, Duner E, Denson LA, Sanz JM, et al. Proinflammatory cytokines inhibit secretion in rat bile duct epithelium. Gastroenterology 2001;121:156-69 (Pubitemid 32591526)
43. Rada B, Leto TL. Pyocyanin effects on respiratory epithelium: relevance in Pseudomonas aeruginosa airway infections. Trends Microbiol 2013;21:73-81
44. Cheluvappa R, Denning GM, Lau GW, Grimm MC, Hilmer SN, Le Couteur DG. Pseudomonas aeruginosa and the hyperlipidaemia of sepsis. Pathology 2009;41:615-21
45. Abildgaard U, Heimdal K. Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review. Eur J Obstet Gynecol Reprod Biol 2013;166:117-23
46. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992-1005 (Pubitemid 44343543)
47. Rolfes DB, Ishak KG. Liver disease in toxemia of pregnancy. Am J Gastroenterol 1986;81:1138-44 (Pubitemid 17216841)
48. Strand S, Strand D, Seufert R, Mann A, Lotz J, Blessing M, et al. Placenta-derived CD95 ligand causes liver damage in hemolysis, elevated liver enzymes, and low platelet count syndrome. Gastroenterology 2004;126:849-58 (Pubitemid 38298333)
49. Rosado FG, Kim AS. Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis. Am J Clin Pathol 2013;139:713-27
50. Bihl F, Emmenegger U, Reichen J, Neftel KA, Zimmermann A, Cerny A. Macrophage activating syndrome is associated with lobular hepatitis and severe bile duct injury with cholestasis. J Hepatol 2006;44:1208-12
51. Billiau AD, Roskams T, Van Damme-Lombaerts R, Matthys P, Wouters C. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6-and TNFalpha-producing macrophages. Blood 2005;105:1648-51 (Pubitemid 40223686)
52. Mansueto P, Vitale G, Cascio A, Seidita A, Pepe I, Carroccio A, et al. New insight into immunity and immunopathology of Rickettsial diseases. Clin Dev Immunol 2011;2012:125-50
53. Cascio A, Pernice LM, Barberi G, Delfino D, Biondo C, Beninati C, et al. Secondary hemophagocytic lymphohistiocytosis in zoonoses. A systematic review. Eur Rev Med Pharmacol Sci 2012;16:1324-37
54. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011;141:1572-85
55. Rank N, Michel C, Haertel C, Lenhart A, Welte M, Meier-Hellmann A, et al. N-acetylcysteine increases liver blood flow and improves liver function in septic shock patients: results of a prospective, randomized, double-blind study. Crit Care Med 2000;28:3799-807 (Pubitemid 32044475)
56. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709 (Pubitemid 32204987)
57. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001;276:11199-203 (Pubitemid 38089304)
58. Guido M, Burra P. De novo autoimmune hepatitis after liver transplantation. Semin Liver Dis 2011;31:71-81
59. Moreno-Merlo F, Wanless IR, Shimamatsu K, Sherman M, Greig P, Chiasson D. The role of granulomatous phlebitis and thrombosis in the pathogenesis of cirrhosis and portal hypertension in sarcoidosis. Hepatology 1997;26:554-60 (Pubitemid 27392343)
60. Liberal R, Grant CR, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: a comprehensive review. J Autoimmun 2013;41: 126-39
61. Carrier P, Godet B, Crepin S, Magy L, Debette-Gratien M, Pillegand B, et al. Acute liver toxicity due to methylprednisolone: consider this diagnosis in the context of autoimmunity. Clin Res Hepatol Gastroenterol 2013;37:100-4
62. Wanless IR, Bargman JM, Oreopoulos DG, Vas SI. Subcapsular steatonecrosis in response to peritoneal insulin delivery: a clue to the pathogenesis of steatonecrosis in obesity. Mod Pathol 1989;2:69-74
63. Sohn J, Siegelman E, Osiason A. Unusual patterns of hepatic steatosis caused by the local effect of insulin revealed on chemical shift MR imaging. AJR Am J Roentgenol 2001;176:471-4 (Pubitemid 32105664)
64. Battaglia DM, Wanless IR, Brady AP, Mackenzie RL. Intrahepatic sequestered segment of liver presenting as focal fatty change. Am J Gastroenterol 1995;90:2238-9
65. Wanless I, Redston MS. The effect of insulin on development of fatty liver in choline deficient rats. Mod Pathol 1991;4:95A
66. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;12:1106-10
67. Leamy AK, Egnatchik RA, Young JD. Molecular mechanisms and the role of saturated fatty acids in the progression of nonalcoholic fatty liver disease. Prog Lipid Res 2013;52:165-74
68. Li Z, Berk M, McIntyre TM, Gores GJ, Feldstein AE. The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology 2008;47:1495-503 (Pubitemid 351702733)
69. Farrell GC, van Rooyen D, Gan L, Chitturi S. NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications. Gut Liver 2012;6:149-71
70. Cha I, Bass N, Ferrell LD. Lipopeliosis. An immunohistochemical and clinicopathologic study of five cases. Am J Surg Pathol 1994;18:789-95 (Pubitemid 24229401)
71. Lottenberg AM, Afonso Mda S, Lavrador MS, Machado RM, Nakandakare ER. The role of dietary fatty acids in the pathology of metabolic syndrome. J Nutr Biochem 2012;23:1027-40
72. Spencer MD, Hamp TJ, Reid RW, Fischer LM, Zeisel SH, Fodor AA. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 2011;140:976-86
73. Machado MV, Cortez-Pinto H. Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol 2012;11:440-9
74. Delzenne NM, Neyrinck AM, Cani PD. Gut microbiota and metabolic disorders: how prebiotic can work? Br J Nutr 2013; 109(Suppl. 2):S81-5
75. Bunout D. Nutritional and metabolic effects of alcoholism: their relationship with alcoholic liver disease. Nutrition 1999; 15:583-9 (Pubitemid 29340039)
76. Sakaguchi S, Takahashi S, Sasaki T, Kumagai T, Nagata K. Progression of alcoholic and non-alcoholic steatohepatitis: common metabolic aspects of innate immune system and oxidative stress. Drug Metab Pharmacokinet 2011;26:30-46
77. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-5
78. Zimmer V, Lammert F. Genetics and epigenetics in the fibrogenic evolution of chronic liver diseases. Best Pract Res Clin Gastroenterol 2011;25:269-80
79. Di Rosa M, Malaguarnera L. Genetic variants in candidate genes influencing NAFLD progression. J Mol Med 2012;90:105-18
80. Dongiovanni P, Valenti L, Rametta R, Daly AK, Nobili V, Mozzi E, et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 2010;59: 267-73
81. Matsui O, Takahashi S, Kadoya M, Yoshikawa J, Gabata T, Takashima T, et al. Pseudolesion in segment IV of the liver at CT during arterial portography: correlation with aberrant gastric venous drainage. Radiology 1994;193:31-5 (Pubitemid 24297993)